Steven Glazer

Drug Development Consultant

2012 - Current

Providing interim C-suite positions as CMO and CDO Drug development plans Preclinical and clinical development advice Regulatory affairs Due Diligence Business development

Chief Medical Officer

2020

MonTa Biosciences is a biotech company working in the immuno-oncology field. Our TLR7 lead candidate MBS8 is a micelle formulation of a small molecule TLR7 agonist.

Partner

2019

Ventac Partner’s is a dedicated life science consulting firm with offices in Europe, USA and Asia. The partner’s form an international team involved in founding, building and growing new life science companies worldwide in partnership with asset stakeholders and investors. Ventac Partner’s support companies by providing a seasoned management team that have hands-on experience in building business plans, negotiate and executing licensing deals and keeping IR, fundraising, M&A and patent portfolio development at best international practice.

Chief Medical Officer

2020 - 2022

Allero Therapeutics develops next generation immunotherapies for allergic and autoimmune disease patients. Its proprietary SOMIT (Specific Oromucosal Immunotherapy) technology is designed to restore long-lasting antigen-specific tolerance.

Medical Director

2018 - 2022

Developing therapeutic cancer vaccine. RhoC is overexpressed in all metastatic cancer cells. The product RhoVac is developing targets RhoC and has the potential to address a broad target group.

Board Member and Chair of Scientific Board

2016 - 2021

Allogenic DC-based immunotherapies, off-the-shelf cell-based therapies The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications.

Chief Medical Officer

2017 - 2019

Idogen develops tolerogenic cell therapies. Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A who have developed anti-drug antibodies coagulation factor VIII (factor VIII). The company also develops IDO T – a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection.

Chief Medical Officer

2015 - 2017

Hansa Medical is a Swedish clinical stage drug development company focused on novel immunomodulatory enzymes for the treatment of rare and acute conditions characterized by pathogenic antibodies. The lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.

SVP Development

2004 - 2012

Director Development

2001 - 2004